https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Leap_Therapeutics%2C_Inc.Leap Therapeutics, Inc. - Revizia istoricului2026-04-06T02:40:46ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Leap_Therapeutics,_Inc.&diff=428921&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Leap Therapeutics, Inc. listata cu simbolul US.LPTX ==Descriere companie== Leap Therapeutics, Inc. (https://www.leaptx.com/) is a biopharmaceutical company. The Company is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company has two product pipelines: DKN-01 and TRX518. The Company's lead clinical stage program...2024-09-18T18:10:13Z<p>Pagină nouă: Pagina dedicata companiei Leap Therapeutics, Inc. listata cu simbolul US.LPTX ==Descriere companie== Leap Therapeutics, Inc. (https://www.leaptx.com/) is a biopharmaceutical company. The Company is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company has two product pipelines: DKN-01 and TRX518. The Company's lead clinical stage program...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Leap Therapeutics, Inc. listata cu simbolul US.LPTX<br />
<br />
==Descriere companie==<br />
Leap Therapeutics, Inc. (https://www.leaptx.com/) is a biopharmaceutical company. The Company is focused on developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company has two product pipelines: DKN-01 and TRX518. The Company's lead clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a cell secreted protein that research has found its role in embryonic development. DKN-01 is an affinity, neutralizing monoclonal antibody targeting DKK1. DKN-01 reduces free DKK1 levels and has demonstrated an anti-tumor effect in preclinical models. TRX518 is a humanized anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody designed for the immune system’s anti-tumor response as an immune checkpoint agonist.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.LPTX" /><br />
<br />
==Ultimele stiri despre Leap Therapeutics, Inc. (US.LPTX)==<br />
<dynamicpagelist><br />
category=US.LPTX<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.LPTX]][[Categorie:Stiri despre companii]]</div>Admin